| Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism AHJ Danser, MADH Schalekamp, WA Bax, AM van den Brink, PR Saxena, ... Circulation 92 (6), 1387-1388, 1995 | 1098 | 1995 |
| Coronary side-effect potential of current and prospective antimigraine drugs A MaassenVanDenBrink, M Reekers, WA Bax, MD Ferrari, PR Saxena Circulation 98 (1), 25-30, 1998 | 352 | 1998 |
| Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of Migraine D Dodick, RB Lipton, V Martin, V Papademetriou, W Rosamond, ... Headache: The Journal of Head and Face Pain 44 (5), 414-425, 2004 | 327 | 2004 |
| Blocking CGRP in migraine patients–a review of pros and cons M Deen, E Correnti, K Kamm, T Kelderman, L Papetti, E Rubio-Beltrán, ... The journal of headache and pain 18, 1-9, 2017 | 322 | 2017 |
| Calcitonin gene-related peptide and its role in migraine pathophysiology U Arulmani, A MaassenVanDenBrink, CM Villalón, PR Saxena European journal of pharmacology 500 (1-3), 315-330, 2004 | 281 | 2004 |
| European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention–2022 update S Sacco, FM Amin, M Ashina, L Bendtsen, CI Deligianni, R Gil-Gouveia, ... The journal of headache and pain 23 (1), 67, 2022 | 271 | 2022 |
| Wiping out CGRP: potential cardiovascular risks A MaassenVanDenBrink, J Meijer, CM Villalón, MD Ferrari Trends in pharmacological sciences 37 (9), 779-788, 2016 | 247 | 2016 |
| Basic mechanisms of migraine and its acute treatment L Edvinsson, CM Villalón, A MaassenVanDenBrink Pharmacology & therapeutics 136 (3), 319-333, 2012 | 203 | 2012 |
| Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans T de Vries, CM Villalón, A MaassenVanDenBrink Pharmacology & Therapeutics 211, 107528, 2020 | 187 | 2020 |
| Animal models of migraine: looking at the component parts of a complex disorder A Bergerot, PR Holland, S Akerman, T Bartsch, AH Ahn, ... European Journal of Neuroscience 24 (6), 1517-1534, 2006 | 170 | 2006 |
| Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of … S Sacco, GS Merki-Feld, KL Ægidius, J Bitzer, M Canonico, T Kurth, ... The journal of headache and pain 18, 1-20, 2017 | 163 | 2017 |
| Potential role of female sex hormones in the pathophysiology of migraine S Gupta, S Mehrotra, CM Villalón, M Perusquía, PR Saxena, ... Pharmacology & therapeutics 113 (2), 321-340, 2007 | 152 | 2007 |
| Gender aspects of CGRP in migraine A Labastida-Ramírez, E Rubio-Beltrán, CM Villalón, ... Cephalalgia 39 (3), 435-444, 2019 | 138 | 2019 |
| Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation W van der Kamp, AM VanDenBrink, MD Ferrari, JG van Dijk Journal of the neurological sciences 139 (1), 106-110, 1996 | 130 | 1996 |
| Giving researchers a headache–sex and gender differences in migraine L Al-Hassany, J Haas, M Piccininni, T Kurth, A Maassen Van Den Brink, ... Frontiers in neurology 11, 549038, 2020 | 127 | 2020 |
| Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? E Rubio-Beltrán, A Labastida-Ramírez, CM Villalón, ... Pharmacology & therapeutics 186, 88-97, 2018 | 117 | 2018 |
| Side effects associated with current and prospective antimigraine pharmacotherapies A González-Hernández, BA Marichal-Cancino, A MaassenVanDenBrink, ... Expert opinion on drug metabolism & toxicology 14 (1), 25-41, 2018 | 109 | 2018 |
| Current understanding of meningeal and cerebral vascular function underlying migraine headache D Levy, A Labastida-Ramirez, A MaassenVanDenBrink Cephalalgia 39 (13), 1606-1622, 2019 | 102 | 2019 |
| Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice IA Mulder, M Li, T de Vries, T Qin, T Yanagisawa, K Sugimoto, ... Annals of neurology 88 (4), 771-784, 2020 | 101 | 2020 |
| Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase A MaassenVanDenBrink, R de Vries, PR Saxena, MADH Schalekamp, ... Cardiovascular research 44 (2), 407-415, 1999 | 99 | 1999 |
